SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is capturing significant attention due to its upcoming $1 million mainnet perpetuals trading competition and the launch of its V3 perps with multi-collateral support on Ethereum. The community is buzzing about the end of SNX token inflation and the start of buybacks, fueling bullish price speculation and increased trading volume.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is trending due to recent integrations with the COTI Network and AR.IO, ongoing "Glacier Drop" airdrop excitement, and mentions of major exchange listings, positioning it as a privacy-focused blockchain within the Cardano ecosystem for institutional adoption. The community is actively debating its growth potential and regulatory compliance compared to other privacy coins, while also discussing its relationship with ADA and associated meme coins like COCK.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is surging after securing FDA approval for BYSANTI with unexpected New Chemical Entity status, providing robust patent protection until 2044, which the community hails as a "Gold Standard" and a significant re-rating event that could attract big pharma. Discussion is focused on this long-term revenue moat and the "mega blockbuster" potential of its Tradipitant for GLP-1 nausea.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is trending after the SEC dismissed its lawsuit and a significant partnership with AT&T emerged, solidifying its role in the DePIN sector. Community sentiment is highly polarized, with strong bullish conviction in its real-world utility and institutional interest contrasting with concerns over project management and token economics for miners.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

JFrog is trending due to a significant stock decline, with the community debating if the move is an overreaction to Anthropic's new AI code security capabilities, and questioning the broader impact on DevSecOps platforms. While some investors see a buying opportunity, others are taking profits or shorting, leading to calls for management to address the market's concerns.

WorldFinancial

WLFI is trending as an upcoming Mar-a-Lago forum, hosted by Trump's sons and featuring notable finance leaders, fuels intense community debate over potential institutional adoption against skepticism and an ongoing US House investigation into foreign investment ties.

KeyCorp is a bank holding company, which engages in the provision of financial services. It operates through the Consumer Bank and Commercial Bank segments. The Consumer Bank segment offers deposit and investment products, personal finance and financial wellness services, lending, mortgage and home equity, student loan refinancing, credit card, treasury services, and business advisory services. The Commercial Bank segment focuses on serving the needs of middle market clients in seven industry sectors, consumer, energy, healthcare, industrial, public sector, real estate, and technology. The company was founded on December 31, 1958 and is headquartered in Cleveland, OH.

Keycorp

KeyCorp is trending as First Citizens BancShares is reportedly exploring a potential acquisition to quickly surpass $250 billion in assets, driving community discussion around the possibility of a takeout and its implications for share repricing. This news comes amidst ongoing chatter about KeyCorp's mixed momentum indicators despite recent revenue growth and strategic restructuring efforts.

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc

MeiraGTx Holdings is garnering significant attention due to its new ophthalmology gene therapy partnership with Eli Lilly and highly positive clinical data for its Parkinson's program, amplifying community belief in the stock's deep undervaluation given its robust pipeline and strategic collaborations with major pharmaceutical companies.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending as its community celebrates a significant anniversary, emphasizing the project's battle-tested resilience and its ongoing delivery of passive Solana rewards to holders. The conversation also highlights new features and liquidity pools that enhance its appeal as a consistent income generator in the crypto space.

Zebra Technologies Corp. engages in the design, manufacture, and sale of automatic identification and data capture products. Its products include mobile computers, barcode scanners, radio frequency identification devices readers, specialty printers for barcode labeling and personal identification, real-time location systems, accessories and supplies, such as self-adhesive labels and other consumables, and software utilities and applications. It also provides services such as maintenance, technical support, repair, and managed and professional services, including cloud-based subscriptions. It operates through Asset Intelligence and Tracking and Enterprise Visibility and Mobility segments. The Asset Intelligence and Tracking segment is involved in barcode and card printing, location solutions, supplies, and services. The Enterprise Visibility and Mobility segment focuses on mobile computing, data capture, and RFID. The company was founded by Edward L. Kaplan and Gerhard Cless in 1969 and is headquartered in Lincolnshire, IL.

Zebra Technologies Corp. - Ordinary Shares - Class A

Zebra Technologies is trending following a strong earnings report that exceeded expectations, alongside the announcement of a substantial stock buyback program. The community is actively discussing bullish momentum and anticipating further upside, driven by the company's robust performance in enterprise automation and strategic moves into AI and robotics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are covering the company, MarketBeat Ratings...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - What's Next?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - Time to Sell...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - Here's Why

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.8% - What's Next...

Cantor Fitzgerald Raises Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target to $19.00

Cantor Fitzgerald upped their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an "overweight" rating in a research report on Thursday...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One...

Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 138.8%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 1,311,773...

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission in EoE patients, with no serious safety issues reported.read more...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 549,299 shares, an increase of...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat...

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

EPRX
Eupraxia Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EPRX News

EPRXEupraxia Pharmaceuticals Inc